STERIS Q3 2021 Earnings Report
Key Takeaways
STERIS announced a 4% increase in revenue to $808.9 million and an increase in earnings per diluted share to $1.33 on a U.S. GAAP basis and $1.73 on an adjusted basis for the fiscal 2021 third quarter ended December 31, 2020.
Third quarter revenue increased 4% as reported and 1% on a constant currency organic basis.
Earnings per diluted share increased to $1.33 on a U.S. GAAP basis and $1.73 on an adjusted basis.
Free cash flow increased due to net income growth and working capital improvements.
Healthcare capital equipment orders continued their sequential improvement, resulting in near record backlog at the end of December.
STERIS
STERIS
STERIS Revenue by Segment
Forward Guidance
STERIS is well positioned to finish another record year in revenue and income during fiscal 2021 and look forward to welcoming Cantel Medical to the STERIS family in fiscal 2022.
Revenue & Expenses
Visualization of income flow from segment revenue to net income